The purpose of this study is to assess the safety and efficacy of using Restylane Silk to reduce the appearance of photoaging on the chest. Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth. This study will compare the appearance of chest wrinkles on half the chest treated with Restylane Silk and the other half, which will be treated with placebo.
Restylane Silk has been safely and effectively used in rejuvenation and appearance of wrinkles in the face. This study seeks to investigate the safety and efficacy of the injectable device in the chest for similar effects. Participants will undergo three treatments with Restylane Silk and results will be measured clinically and with Optical Coherence Tomography (an FDA-cleared non-invasive imaging device). Participants will receive randomized injections with the Restylane Silk product on half of the chest and will receive placebo injections on the other half. At the six-month period, participants will have the option to receive treatment with the product on the placebo side. At the 12-month period, participants may also elect for three additional touch-up treatments, which will not be counted as part of the study. If the chest is asymmetric in regards to wrinkles, the investigators will still proceed with the protocol because they are also comparing each side to itself prior to treatment, instead of simply comparing one side to the other.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
Saline as placebo
An FDA-cleared non-invasive imaging device
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Change in Fabi-Bolton (FB) clinometric chest wrinkle scale
The change from baseline in blinded evaluator assessments of chest/décolletage and 6 months assessed by the Fabi-Bolton (FB) chest wrinkle. The Fabi-Bolton (F-B) 5-point wrinkle scale (1 = wrinkles absent; 2 = shallow but visible wrinkles; 3 = moderately deep wrinkles; 4 = deep wrinkles, with well-defined edges; 5 = wrinkles very deep with redundant folds).
Time frame: Baseline and 6 months
Incidence of reported treatment emergent adverse events
The incidence of reported treatment emergent adverse events
Time frame: up to 360 days
Change in dermal thickness
Achieving statistically significant changes in optical coherence tomography (OCT) (epidermal, papillary, and visible reticular dermal thickness) at 6 months after 3 treatment sessions given
Time frame: Baseline and 6 months
Change in papillary dermal brightness
Achieving statistically significant changes in OCT parameters (papillary dermal brightness) at day 180 after 3 treatment sessions given
Time frame: Baseline and 6 months
Change in upper dermal reflectivity
Achieving statistically significant changes in OCT parameters (upper dermal reflectivity) at day 180 after 3 treatment sessions given
Time frame: Baseline and 6 months
Change in dermoepidermal contrast
Achieving statistically significant changes in OCT parameters (dermoepidermal contrast) at day 180 after 3 treatment sessions given
Time frame: Baseline and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in surface contouring
Achieving statistically significant changes in OCT parameters (surface contouring) at day 180 after 3 treatment sessions given
Time frame: Baseline and 6 months
Patient satisfaction
The questionnaire consists of two "Yes/No" questions (score 0 or 1) and five questions using a 5 point Likert rating scale with scores ranging from 0 (extremely dissatisfied) to 5 (extremely satisfied). The total score range is from 0-27.
Time frame: 6 months